Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn’s Disease Under Combined Immunosuppression: Escalation versus Early Treatment
Open Access
- 19 April 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (11), 1279-1286
- https://doi.org/10.1093/ecco-jcc/jjw086
Abstract
We aimed to compare the efficacy of combined immunosuppression in terms of mucosal healing in paediatric patients with moderate-to-severe luminal Crohn’s disease receiving infliximab according to either an ‘escalated combined immunosuppression’ or an ‘early combined immunosuppression’ strategy. In this prospective observational study, the efficacy of combined immunosuppression was evaluated in terms of mucosal healing at weeks 14 and 54 from baseline infliximab infusion. Comparison was performed between the escalated combined immunosuppression group [group A] and the early combined immunosuppression group [group B]. Factors associated with mucosal healing at weeks 14 and 54 from baseline infliximab infusion were also investigated. Seventy-six patients initiated infliximab with concomitant azathioprine [group A = 28; group B = 48]. Comparison of baseline characteristics revealed a significantly longer duration from initial diagnosis to infliximab infusion in group A [median 8.1 vs. 0.7 months; p < 0.001]. Mucosal healing was achieved in 32% of patients in group A and 51% in group B at week 14 [p = 0.121], and in 42% in group A and 74% in group B at week 54 [p = 0.007]. Group B was also positively associated with mucosal healing at week 54 on multivariate logistic regression [odds ratio = 6.216, 95% confidence interval = 1.782–21.686, p = 0.004]. Mucosal healing during combined immunosuppression is more effectively achieved by treatment with an early combined immunosuppression strategy without corticosteroid induction administered within 1 month rather than escalating to receive combination therapy later during the course. The therapeutic window of opportunity in early Crohn’s disease may be shorter than generally thought, especially in children.Keywords
This publication has 32 references indexed in Scilit:
- Mucosal Healing in Crohnʼs DiseaseInflammatory Bowel Diseases, 2013
- Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's diseaseScandinavian Journal of Gastroenterology, 2013
- Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel DiseasePediatric Gastroenterology, Hepatology & Nutrition, 2013
- The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn’s diseaseEuropean Journal of Gastroenterology & Hepatology, 2012
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Anti‐infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot studyThe Journal of Dermatology, 2010
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's DiseaseGastroenterology, 2010
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Liquid Chromatography–Tandem Mass Spectrometry Analysis of Erythrocyte Thiopurine Nucleotides and Effect of Thiopurine Methyltransferase Gene Variants on These Metabolites in Patients Receiving Azathioprine/6-Mercaptopurine TherapyClinical Chemistry, 2005
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004